David Evans, May 20, 2011
This article examines antitrust analysis when one of the possible subject products of an antitrust or merger is ordinarily offered at a zero price. It shows that businesses often offer a product for free because it increases the overall profits they can earn from selling the free product and a companion product to either the same customer or different customers. The companion product may be a complement, a premium version of the free product, or the product on the other side of a two-sided market. The article then shows how antitrust and merger analysis should proceed when the subject is either the free product or the companion product. A key point is that the existence of a free good signals that there is a companion good, that firms consider both products simultaneously in maximizing profit, and that commonly used methods of antitrust analysis, including market definition, probably need to be adjusted to properly analyze two inextricably linked products. When antitrust or merger analysis involves a free product, the analysis of consumer welfare and injury also needs to account for customers of both the free product and its companion product since any change in market conditions for customers of one product affects the customers of the other product. Much of the analysis of the article is also relevant to other common situations in which price is set less than marginal cost.
Links to Full Content
Featured News
Congress Pushes to Combat AI Deepfakes in Year-End Funding Deal
Dec 18, 2024 by
CPI
Epic Games Board Resignations Linked to DOJ Antitrust Investigation
Dec 18, 2024 by
CPI
Renault Supports Potential Honda-Nissan Merger Talks
Dec 18, 2024 by
CPI
South Korea’s Antitrust Body Raises Concerns Over AI Market Competition
Dec 18, 2024 by
CPI
Perplexity Caught in Crossfire as DOJ and Google Battle Over Search Dominance
Dec 18, 2024 by
CPI
Antitrust Mix by CPI
Remedies After Illumina/GRAIL– The Thorny Question of Proportionality
Dec 17, 2024 by
Aleksander Tombinski & Ciara Denihan
Why Was Illumina/GRAIL Blocked in the EU? Reviewing The European Commission’s Assessment of Vertical Mergers in Light of the 2022 Prohibition Decision
Dec 17, 2024 by
Will Sparks
The Role of Uncertainty in the Future European Horizontal Merger Guidelines: Lessons Learned From Illumina/GRAIL
Dec 17, 2024 by
Svend Albaek & Daniel Donath
Illumina’s Light on Article 22 EUMR: The Suspended Step and Uncertain Future of EU Merger Control Over Below-Threshold “Killer” Mergers
Dec 17, 2024 by
Anna Tzanaki
EU-Level Jurisdiction Over “Killer Acquisitions” in the Aftermath of Illumina/GRAIL
Dec 17, 2024 by
Peter Whelan